AYTU
Aytu BioScience, Inc. Proforma Balance Sheet BiopharmaWatch Research Key Takeaway: Aytu BioScience, Inc. Proforma Balance Sheet June 30, 2017 Unaudited
6/30/2017 Pro Forma Pro Forma Consolidated Adjustments (a) Combined (b) Assets Current assets Cash and cash equivalents $ 802,328 $ 10,637,752 $ 11,440,080 Restricted cash
BiopharmaWatch Analysis From our catalyst data and publicly available data · not financial advice Cash runway
~16 mo
Low dilution risk
Lead asset
NT0102
Phase 3 · Attention Deficit Hyperactivity Disorder (ADHD)
Full Press Release Details Aytu BioScience, Inc. Proforma Balance Sheet June 30, 2017 Unaudited
6/30/2017 Pro Forma Pro Forma Consolidated Adjustments (a) Combined (b) Assets Current assets Cash and cash equivalents $ 802,328 $ 10,637,752 $ 11,440,080 Restricted cash 75,214 75,214 Accounts receivable, net 528,039 - 528,039 Inventory, net 1,312,221 - 1,312,221 Prepaid expenses and other 310,760 - 310,760 Total current assets 3,028,562 10,637,752 13,666,314 Fixed assets, net 647,254 - 647,254 Developed technology, net 1,337,333 - 1,337,333 Customer contracts, net 77,667 - 77,667 Trade names, net 164,037 - 164,037 Natesto asset 9,231,072 - 9,231,072 Goodwill 238,426 - 238,426 Patents, net 271,278 - 271,278 Deposits 2,888 - 2,888 Total long-term assets 11,969,955 - 11,969,955 Total assets $ 14,998,517 $ 10,637,752 $ 25,636,269 Liabilities and Stockholders' Equity Current liabilities Accounts payable and other $ 2,220,400 $ - $ 2,220,400 Accrued liabilities 782,536 - 782,536 Accrued compensation 339,704 - 339,704 Deferred rent 6,673 - 6,673 Contingent consideration 261,155 - 261,155 Warrant derivative liability - 3,323,411 3,323,411 Total current liabilities 3,610,468 3,323,411 6,933,879 Contingent consideration 7,386,782 - 7,386,782 Deferred rent 1,451 - 1,451 Total liabilities 10,998,701 3,323,411 14,322,112 Commitments and contingencies Stockholders' equity Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued - 1 1 Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 824,831 in 2017 and 187,098 in 2016 82 320 402 Additional paid-in capital 73,069,463 7,314,020 80,383,483 Accumulated deficit (69,069,729 ) - (69,069,729 ) Total stockholders' equity 3,999,816 7,314,341 11,314,157 - Total liabilities and stockholders' equity $ 14,998,517 $ 10,637,752 $ 25,636,269
Tags: AYTU Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare